Lopinavir/ritonavir es una combinación fija de antivirales ampliamente utilizada para tratar la infección por VIH. En el marco de la pandemia por COVID-19 en 2019/2020, se ha sugerido que puede constituir un tratamiento para esta enfermedad.
Categoría: Investigaciones y estudios
Investigaciones y estudios
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Hydroxychloroquine and azithromycin as a treatment of COVID-19
Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be efficient in Chinese COV-19 patients. We evaluate the role of hydroxychloroquine on respiratory viral loads.
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression
A novel coronavirus disease (COVID-19), caused by infection with SARS-CoV-2, has swept across 31 provinces in China and over 40 countries worldwide. The transition from first symptoms to acute respiratory distress syndrome (ARDS) is highly likely to be due to uncontrolled cytokine release.
Azithromycin induces anti-viral responses in bronchial epithelial cells
Respiratory viral infections are associated with the majority of asthma exacerbations (,80%) in both adults [1, 2] and children [3, 4]. Asthma exacerbations are the major cause of morbidity, mortality and healthcare costs in asthma [5].
Angiotensin‑converting enzyme 2 (ACE2) as a SARS‑CoV‑2 receptor: molecular mechanisms and potential therapeutic target
A novel infectious disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was detected in Wuhan, China, in December 2019. The disease (COVID-19) spread rapidly, reaching epidemic proportions in China, and has been found in 27 other countries.